En randomisert sammenligning av personlig pleie basert på hjertesykdomsstadie versus vanlig pleie for forebygging av hendelser (TRANSFORM)
En randomisert sammenligning av personlig pleie basert på stadieinndeling av koronararteriesykdom versus vanlig pleie for primær forebygging av kardiovaskulære hendelser
TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
Cardiovascular disease (CVD) persists as the leading cause of morbidity and mortality worldwide at high societal cost. The current primary CVD prevention strategy relies upon risk stratification using population health markers such as age, sex, diabetes, hypertension, dyslipidemia and tobacco use, with preventive therapy intensified in higher risk strata. Since these risk factors are indirect surrogate markers of the underlying disease, atherosclerosis, this strategy leads to treatment of individuals with risk factors who do not have atherosclerosis and failure to treat those with significant atherosclerosis who lack risk factors. The current strategy also cannot determine which individuals are inadequately treated despite effective risk factor management (residual risk). With the current approach, the CV death rate is trending upward in the US despite evidence that screening asymptomatic patients reduces CV events and the widespread availability of effective preventive therapies.
This randomized, controlled, pragmatic trial is designed to address the unmet need for better strategies to identify asymptomatic individuals at increased risk for CV events due to atherosclerosis and to personalize their treatment based on CV risk estimates using coronary artery disease (CAD) visualization and quantification.
This study enrolls patients without known symptoms of ASCVD but who are at increased risk for ASCVD due to their age and having diabetes, prediabetes or metabolic syndrome and tests the hypothesis that a CAD Staging System-based care strategy reduces CV events compared with risk factor-based care. The Cleerly CAD Staging System incorporates imaging-based evaluation for coronary atherosclerosis, algorithm-supported pharmacotherapy and personalized education about their CAD.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Ryann Sardinia
- Telefonnummer: 7207398191
- E-post: ryann.sardinia@cleerlyhealth.com
Studer Kontakt Backup
- Navn: Ashley Dunham, PhD
- Telefonnummer: 7207398191
- E-post: ashley.dunham@cleerlyhealth.com
Studiesteder
-
-
Arizona
-
Chandler, Arizona, Forente stater, 85224
- Rekruttering
- Chandler Clinical Trials
-
Ta kontakt med:
- Muhammad Salim, MD
-
Scottsdale, Arizona, Forente stater, 85260
- Rekruttering
- Scottsdale Clinical Trials
-
Ta kontakt med:
- Todd Dreitzler, MD
-
Sun City, Arizona, Forente stater, 85381
- Rekruttering
- Sun City Research
-
Ta kontakt med:
- Juan Rodriguez, MD
-
Tucson, Arizona, Forente stater, 85704
- Rekruttering
- Noble Clinical Research
-
Ta kontakt med:
- Roxana Rodriguez, MD
-
-
California
-
Beverly Hills, California, Forente stater, 90210
- Rekruttering
- Cardiovascular Research Foundation of Southern California
-
Ta kontakt med:
- Ronald P. Karlsberg, MD
-
Beverly Hills, California, Forente stater, 90211
- Rekruttering
- Amicis Research: Beverly Hills
-
Ta kontakt med:
- Michael Levine, MD
-
Canoga Park, California, Forente stater, 91303
- Rekruttering
- Valiance Clinical Research - Canoga Park
-
Ta kontakt med:
- Rami Shaarawy
-
Chula Vista, California, Forente stater, 91911
- Rekruttering
- Cardiovascular Institute of San Diego
-
Ta kontakt med:
- Milind D. Parikh, MD
-
Granada Hills, California, Forente stater, 91324
- Rekruttering
- Amicis Research: Granada Hills
-
Ta kontakt med:
- Pascal Dabel, MD
-
Huntington Park, California, Forente stater, 90255
- Rekruttering
- Valiance Clinical Research: Huntington Park
-
Ta kontakt med:
- Philip Kim, MD
-
Indian Wells, California, Forente stater, 92210
- Rekruttering
- HALO Diagnostics
-
Ta kontakt med:
- John F. Feller, MD
-
La Jolla, California, Forente stater, 92037
- Rekruttering
- Scripps Health
-
Ta kontakt med:
- Elizabeth Epstein, MD
-
Lancaster, California, Forente stater, 93534
- Rekruttering
- Chemidox Clinical Trials
-
Ta kontakt med:
- Pamela Dewar-DeSilva, MD
-
Loma Linda, California, Forente stater, 92354
- Rekruttering
- Loma Linda University Health
-
Ta kontakt med:
- Purvi Parwani, MD
-
Long Beach, California, Forente stater, 90805
- Rekruttering
- Long Beach Research Institute
-
Ta kontakt med:
- Ashley Duzik, MD
-
Monterey Park, California, Forente stater, 91754
- Rekruttering
- Ace Research Institute - Monterey Park
-
Ta kontakt med:
- Yu-Hsiang Sam Lee, MD
-
Newhall, California, Forente stater, 91321
- Rekruttering
- Amicis Research: Newhall
-
Ta kontakt med:
- Thuong Vo, MD
-
Northridge, California, Forente stater, 91324
- Rekruttering
- Ace Research Institute: Northridge
-
Ta kontakt med:
- Richard Park, MD
-
Northridge, California, Forente stater, 91324
- Rekruttering
- Amicis Research: Northridge
-
Ta kontakt med:
- Nana Barseghian, MD
-
Northridge, California, Forente stater, 91325
- Rekruttering
- Ace Research Institute: Northridge #2
-
Ta kontakt med:
- William Y. Josephson, MD
-
Northridge, California, Forente stater, 91325
- Aktiv, ikke rekrutterende
- Northridge Clinical Trials
-
Orange, California, Forente stater, 92868
- Rekruttering
- University of California- Irvine
-
Ta kontakt med:
- Ailin Barseghian El-Farra, MD
-
Palo Alto, California, Forente stater, 94304
- Rekruttering
- Stanford Health Care
-
Ta kontakt med:
- Sandra Tsai, MD
-
Palo Alto, California, Forente stater, 94304
- Rekruttering
- VA Palo Alto
-
Ta kontakt med:
- Shriram Nallamshetty, MD
-
San Fernando, California, Forente stater, 91306
- Rekruttering
- Amicis Research: San Fernando
-
Ta kontakt med:
- Farid Yasharpour, MD
-
Tarzana, California, Forente stater, 91356
- Rekruttering
- Valiance Clinical Research - Tarzana
-
Ta kontakt med:
- Harpreet Singh, MD
-
Torrance, California, Forente stater, 90502
- Rekruttering
- Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center
-
Ta kontakt med:
- Suvasini Lakshmanan, MD
-
Valencia, California, Forente stater, 91355
- Rekruttering
- Amicis Research: Valencia
-
Ta kontakt med:
- Dennis Lewis, MD
-
Valley Village, California, Forente stater, 91607
- Rekruttering
- Concierge Clinical Trials
-
Ta kontakt med:
- Neal R. Cutler, MD
-
-
Colorado
-
Aurora, Colorado, Forente stater, 80045
- Rekruttering
- University of Colorado
-
Ta kontakt med:
- Steve Simon
-
Hovedetterforsker:
- Steve Simon, MD
-
Denver, Colorado, Forente stater, 80218
- Rekruttering
- St. Josephs (Intermountain Healthcare)
-
Ta kontakt med:
- Christopher Angus, MD
-
-
Florida
-
Boca Raton, Florida, Forente stater, 33434
- Rekruttering
- Flourish Medical Research
-
Ta kontakt med:
- Michael Hafran, MD
-
Cross City, Florida, Forente stater, 32628
- Rekruttering
- Apex Research
-
Ta kontakt med:
- Tamir Salmani, MD
-
Hialeah, Florida, Forente stater, 33012
- Rekruttering
- Evolution Research Center
-
Ta kontakt med:
- Riquel Gonzalez, MD
-
Jacksonville, Florida, Forente stater, 32209
- Rekruttering
- UF Health Jacksonville
-
Ta kontakt med:
- Luis Ortega Paz, MD
-
Miami, Florida, Forente stater, 33137
- Rekruttering
- BioPhase Research
-
Ta kontakt med:
- Julie Cadet-Plassman, MD
-
Miami, Florida, Forente stater, 33135
- Rekruttering
- Fiel Wellness Clinical Research LLC
-
Ta kontakt med:
- Osvaldo Caroma, MD
-
Miami, Florida, Forente stater, 33155
- Rekruttering
- United Clinical Research
-
Ta kontakt med:
- Teresa B. Alfonso, MD
-
Ta kontakt med:
- Alfonso
-
Miami, Florida, Forente stater, 33173
- Rekruttering
- Atlantis Clinical Research, LLC
-
Ta kontakt med:
- Leyvi Alvarado Miranda, MD
-
Miami, Florida, Forente stater, 33183
- Rekruttering
- Farma Medical Inc.
-
Ta kontakt med:
- Ingrid Fernandez-Milian, MD
-
Miami, Florida, Forente stater, 33173
- Rekruttering
- Baptist Health Miami Cardiac and Vascular Institute
-
Ta kontakt med:
- Jonathan Fialkow, MD
-
Miami, Florida, Forente stater, 33186
- Rekruttering
- New Access Research and Medical Center
-
Ta kontakt med:
- Sander Fernandez, MD
-
Miami Beach, Florida, Forente stater, 33140
- Rekruttering
- Quantum Clinical Trials
-
Ta kontakt med:
- Christopher A. Fayeghi, MD
-
Pensacola, Florida, Forente stater, 32504
- Rekruttering
- Ascension Sacred Heart
-
Ta kontakt med:
- Rohit Amin, MD
-
Pompano Beach, Florida, Forente stater, 33060
- Rekruttering
- Clinical Research Center of Florida
-
Ta kontakt med:
- Howard S. Koch, MD
-
Tampa, Florida, Forente stater, 33620
- Rekruttering
- University of South Florida
-
Ta kontakt med:
- Shone Almeida, MD
-
-
Georgia
-
Augusta, Georgia, Forente stater, 30907
- Rekruttering
- Aiyan Diabetes Center
-
Ta kontakt med:
- Anthony D. Turner, MD
-
Dunwoody, Georgia, Forente stater, 30338
- Rekruttering
- Emory University
-
Ta kontakt med:
- Ambar Kulshreshtha, MD
-
Fayetteville, Georgia, Forente stater, 30214
- Rekruttering
- Privia Medical Group Georgia LLC -Fayetteville (Javara)
-
Ta kontakt med:
- Charlotte Grayson Mathis, MD
-
Lithia Springs, Georgia, Forente stater, 30122
- Rekruttering
- Randomize Now- Atlanta West
-
Ta kontakt med:
- Millard Collier Jr., MD
-
Macon, Georgia, Forente stater, 31210
- Rekruttering
- Randomize Now-Burton Medical
-
Ta kontakt med:
- Frederick Burton, MD
-
Norcross, Georgia, Forente stater, 30092
- Rekruttering
- Evergreen Clinical Trials
-
Ta kontakt med:
- Dmitriy Pelishev, MD
-
Powder Springs, Georgia, Forente stater, 30127
- Rekruttering
- Peachtree Clinical Solutions - Noir Research Collective
-
Ta kontakt med:
- Karan Raghavan, MD
-
Riverdale, Georgia, Forente stater, 30296
- Rekruttering
- Randomize Now, LLC - Noir Research Collective
-
Ta kontakt med:
- Claire K. Willie, MD
-
Savannah, Georgia, Forente stater, 31406
- Rekruttering
- Privia Medical Group Georgia, LLC (Javara Inc.)
-
Ta kontakt med:
- Thomas G. Moriarity, MD
-
Thomasville, Georgia, Forente stater, 31792
- Rekruttering
- Privia Medical Group Georgia - Thomasville (Javara)
-
Ta kontakt med:
- William L. Cooper, MD
-
-
Idaho
-
Meridian, Idaho, Forente stater, 83642
- Rekruttering
- Care Institute- High Desert
-
Ta kontakt med:
- David A. Hinchman, MD
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Rekruttering
- Northwestern University
-
Ta kontakt med:
- Paul C. Cremer, MD
-
Glenview, Illinois, Forente stater, 60026
- Rekruttering
- Northshore University Health System
-
Ta kontakt med:
- Amit K. Pursnani, MD
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46237
- Rekruttering
- Franciscan Physician Network- Indiana Heart Physicians
-
Ta kontakt med:
- Ryan P Daly, MD
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana Medical Research Institute
-
Ta kontakt med:
- Arshad P. Malik
-
-
Iowa
-
West Des Moines, Iowa, Forente stater, 50266
- Rekruttering
- MercyOne Iowa Heart Center
-
Ta kontakt med:
- Enrico L. Martin, MD
-
-
Kentucky
-
Edgewood, Kentucky, Forente stater, 41017
- Rekruttering
- St Elizabeth Health Care - CRI
-
Ta kontakt med:
- Erica Pivato, MD
-
Louisville, Kentucky, Forente stater, 40202
- Rekruttering
- UofL Health
-
Ta kontakt med:
- Shahab Ghafghazi, MD
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70127
- Rekruttering
- Ascension DePaul Services Research Center
-
Ta kontakt med:
- Kristen Thomas, MD
-
-
Maryland
-
Bowie, Maryland, Forente stater, 20715
- Rekruttering
- Flourish Bowie dba Flourish Research
-
Ta kontakt med:
- Sara Collins, MD
-
Columbia, Maryland, Forente stater, 21045
- Rekruttering
- KUR Research at CMP
-
Ta kontakt med:
- William Saway, MD
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02115
- Rekruttering
- Brigham and Women's Hospital
-
Ta kontakt med:
- Ron Blankstein, MD
-
Boston, Massachusetts, Forente stater, 02114
- Rekruttering
- Massachusetts General Hospital
-
Ta kontakt med:
- Pradeep Natarajan, MD
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202
- Rekruttering
- Henry Ford Hospital
-
Ta kontakt med:
- Cori E Russell, MD
-
Ypsilanti, Michigan, Forente stater, 48917
- Rekruttering
- Trinity Health Michigan Heart
-
Ta kontakt med:
- Ahmad Mizyed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Forente stater, 55407
- Rekruttering
- Minneapolis Heart Institute Foundation
-
Ta kontakt med:
- Michael D. Miedema, MD
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Rekruttering
- Washington University School of Medicine
-
Ta kontakt med:
- Farhan M. Katchi, MD
-
St Louis, Missouri, Forente stater, 63136
- Rekruttering
- Saint Louis Heart and Vascular
-
Ta kontakt med:
- Gil Vardi, MD
-
-
Montana
-
Kalispell, Montana, Forente stater, 59901
- Rekruttering
- Boeson Research Kalispell
-
Ta kontakt med:
- Justin Buls, MD
-
Missoula, Montana, Forente stater, 59804
- Rekruttering
- Boeson Research Fort Missoula
-
Ta kontakt med:
- Audrey Remmers, MD
-
-
Nebraska
-
Lincoln, Nebraska, Forente stater, 68506
- Rekruttering
- Bryan Heart
-
Ta kontakt med:
- Chad E. Travers, MD
-
-
Nevada
-
Las Vegas, Nevada, Forente stater, 89128
- Rekruttering
- Vector Clinical Trials
-
Ta kontakt med:
- Bharat R. Mocherla, MD
-
Las Vegas, Nevada, Forente stater, 89102
- Rekruttering
- Southwest Medical Associates- Optum Nevada
-
Ta kontakt med:
- Tatiana O. Tsvetkova, MD
-
-
New Jersey
-
Flemington, New Jersey, Forente stater, 08822
- Rekruttering
- Advanced Heart and Vascular Institute of Hunterdon
-
Ta kontakt med:
- Andrey Espinoza, MD
-
Marlton, New Jersey, Forente stater, 08053
- Rekruttering
- Virtua Health, Inc.
-
Ta kontakt med:
- Mark T. Finch, MD
-
New Brunswick, New Jersey, Forente stater, 08901
- Rekruttering
- Rutgers State University
-
Ta kontakt med:
- Sabahat Bokhari, MD
-
Paramus, New Jersey, Forente stater, 07652
- Rekruttering
- The Valley Hospital
-
Ta kontakt med:
- Himanshu Gupta, MD
-
Teaneck, New Jersey, Forente stater, 07666
- Rekruttering
- Holy Name Medical Center
-
Ta kontakt med:
- Jaffar Raza, MD
-
-
New York
-
Brooklyn, New York, Forente stater, 11221
- Rekruttering
- Clindove Research
-
Ta kontakt med:
- Nelly Cohen, MD
-
Brooklyn, New York, Forente stater, 11226
- Rekruttering
- Swift Clinical Research
-
Ta kontakt med:
- Manoj Dalmia, MD
-
Jackson Heights, New York, Forente stater, 11372
- Rekruttering
- Rasaj Research
-
Ta kontakt med:
- Ammara Mushtaq, MD
-
Lake Success, New York, Forente stater, 11042
- Rekruttering
- Optum- Long Island NY
-
Ta kontakt med:
- Steven Goldberg, MD
-
Mount Kisco, New York, Forente stater, 10549
- Rekruttering
- Northwell Health Northern Westchester Hospital
-
Ta kontakt med:
- Margaret Andersen, MD
-
New York, New York, Forente stater, 10019
- Rekruttering
- Mount Sinai West
-
Ta kontakt med:
- Waqas A Malick, MD
-
New York, New York, Forente stater, 10029
- Rekruttering
- Mount Sinai
-
Ta kontakt med:
- Solomon Bienstock, MD
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- Rekruttering
- University of North Carolina at Chapel Hill
-
Ta kontakt med:
- Matthew Cavender, MD
-
Durham, North Carolina, Forente stater, 27701
- Rekruttering
- Duke University Hospital
-
Ta kontakt med:
- William Yancy, MD
-
Durham, North Carolina, Forente stater, 27705
- Rekruttering
- Durham Veterans Affairs Medical Center (Durham VAMC)
-
Ta kontakt med:
- Hayden Bosworth, MD
-
Fayetteville, North Carolina, Forente stater, 28304
- Rekruttering
- Cape Fear Valley Health System (Javara Inc.)
-
Ta kontakt med:
- Nafisa Saleem, MD
-
Morehead City, North Carolina, Forente stater, 28557
- Aktiv, ikke rekrutterende
- West Clinical Research
-
Winston-Salem, North Carolina, Forente stater, 27157
- Rekruttering
- Wake Forest University Health Sciences
-
Ta kontakt med:
- Michael Shapiro, MD
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58102
- Rekruttering
- Sanford Health
-
Ta kontakt med:
- David J. Clardy, MD
-
-
Ohio
-
Akron, Ohio, Forente stater, 44304
- Rekruttering
- Summa Health
-
Ta kontakt med:
- Wissam Alajaji, MD
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73109
- Rekruttering
- Medical Research International, LLC
-
Ta kontakt med:
- Joseph Grillo, MD
-
Oklahoma City, Oklahoma, Forente stater, 73007
- Rekruttering
- Hightower Clinical
-
Ta kontakt med:
- Faisal Latif, MD
-
Tulsa, Oklahoma, Forente stater, 74104
- Rekruttering
- Ascension St. John - Jane Phillips Medical Center
-
Ta kontakt med:
- Michael Megaly, MD
-
-
Pennsylvania
-
Camp Hill, Pennsylvania, Forente stater, 17011
- Rekruttering
- Capital Area Research
-
Ta kontakt med:
- Venkatesh Nadar, MD
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29425
- Rekruttering
- Medical University of South Carolina
-
Ta kontakt med:
- Marc-Andre Cornier, MD
-
-
Tennessee
-
Cleveland, Tennessee, Forente stater, 37312
- Rekruttering
- Community DPC
-
Ta kontakt med:
- Carlton Volberg, MD
-
Knoxville, Tennessee, Forente stater, 37920
- Rekruttering
- University of Tennessee Medical Center
-
Ta kontakt med:
- Kashif A. Shaikh, MD
-
Nashville, Tennessee, Forente stater, 37202
- Rekruttering
- TriStar Centennial Medical Center (HCA Health Care)
-
Ta kontakt med:
- David Huneycutt, MD
-
-
Texas
-
Abilene, Texas, Forente stater, 79601
- Rekruttering
- Hendrick Health
-
Ta kontakt med:
- Ren Zhang, MD
-
Beaumont, Texas, Forente stater, 77702
- Rekruttering
- Gadolin Research
-
Ta kontakt med:
- John T Fowler, MD
-
Greenville, Texas, Forente stater, 75402
- Rekruttering
- CardioVoyage, LLC
-
Ta kontakt med:
- Marc Demyun, MD
-
Houston, Texas, Forente stater, 77025
- Rekruttering
- Kelsey Research Foundation
-
Ta kontakt med:
- Rohan R Wagle, MD
-
Houston, Texas, Forente stater, 77004
- Rekruttering
- Helium Research Group
-
Ta kontakt med:
- Ijeoma A. Ekeruo
-
Houston, Texas, Forente stater, 77070
- Rekruttering
- Gulf Coast Clinical Research, LLC
-
Ta kontakt med:
- Anjani Pandya, MD
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- The Methodist Hospital, DeBakey Cardiology Associates
-
Ta kontakt med:
- Sadeer Al-Kindi, MD
-
Laredo, Texas, Forente stater, 78041
- Rekruttering
- Aeres Clinical Research
-
Ta kontakt med:
- Amando Garza, MD
-
Lewisville, Texas, Forente stater, 75057
- Rekruttering
- DC Clinical Research
-
Ta kontakt med:
- Moiz M. Shafiq, MD
-
McKinney, Texas, Forente stater, 75069
- Rekruttering
- North Dallas Research Associates - Kerlo Network
-
Ta kontakt med:
- Muhammad Akram Khan, MD
-
Mesquite, Texas, Forente stater, 75149
- Rekruttering
- SMS Clinical Research
-
Ta kontakt med:
- Salma Saiger, MD
-
San Marcos, Texas, Forente stater, 78666
- Rekruttering
- Privia Medical Group Gulf Coast, PLLC ( Javara Inc.)
-
Ta kontakt med:
- Alan Lee, MD
-
Stephenville, Texas, Forente stater, 76401
- Rekruttering
- Privia Medical Group- North Texas
-
Ta kontakt med:
- Benjamin Marcum, MD
-
-
Utah
-
West Valley City, Utah, Forente stater, 84120
- Har ikke rekruttert ennå
- Kalo Clinical Research
-
Ta kontakt med:
- William J. Walsh, MD
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23225
- Rekruttering
- Chippenham Johnston Willis Medical Center
-
Ta kontakt med:
- Michael Arcarese, MD
-
-
Washington
-
Everett, Washington, Forente stater, 98201
- Rekruttering
- Providence Regional Medical Center Everett
-
Ta kontakt med:
- Xiaojing Jennie Shen, MD
-
Seattle, Washington, Forente stater, 98195
- Rekruttering
- University of Washington
-
Ta kontakt med:
- Kelley Branch, MD
-
-
West Virginia
-
Charleston, West Virginia, Forente stater, 25304
- Rekruttering
- Charleston Area Medical Center
-
Ta kontakt med:
- Sarah Rinehart, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Provided electronic or written informed consent
-
Men > 55, women > 65 years of age
-
Type 2 diabetes mellitus requiring pharmacologic therapy or with their most recent A1c 6.5%. Patients with prediabetes (most recent HbA1c 5.7 to 6.4% and/or fasting glucose 100-125 mg/dL [5.6-6.9 mmol/L]) and/or metabolic syndrome can be enrolled through 12 October 2026 and proceed with randomization; however, no additional participants may enroll with these criteria after this date. Metabolic syndrome is defined as > 3 of the following criteria (International Diabetes Federation 2006):
- Body mass index ≥ 27 kg/m2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)
- Fasting triglycerides ≥ 150 mg/dL (1.7 mmol/L) or treated hypertriglyceridemia
- HDL-cholesterol (HDL-C) < 40 mg/dL (1.03 mmol/L) in men, <50 mg/dL (1.29 mmol/L) in women or treatment for this lipid abnormality
- Systolic blood pressure (BP) ≥ 130 and/or diastolic BP≥ 85 mm Hg and/or treated hypertension
- Fasting blood glucose ≥ 100 mg/dL (5.6 mmol/L) or HbA1c ≥ 5.7%
-
Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group
Exclusion Criteria:
-
Any one of the following:
- A history of acute myocardial infarction (heart attack), stroke, or non-traumatic leg/foot/toe amputation
- A history of an arterial revascularization procedure for coronary, peripheral, and/or carotid atherosclerotic disease (i.e. coronary stent or bypass, carotid stent)
- Symptoms suspicious of coronary artery disease, stroke or peripheral artery disease confirmed by a diagnostic test within the last 12 months (i.e. nuclear stress test, invasive angiogram, brain MRI/CT
- Asymptomatic ASCVD including treatment with therapies (e.g. antiplatelets, lipid lowering) intended to reduce CV risk due to the imaging evidence of atherosclerosis and/or management to goals consistent with secondary prevention guidelines (e.g. LDL-C < 70 mg/dL)
-
Planned arterial revascularization
-
Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:
- eGFR < 60 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org/professionals/kdoqi/gfr_calculator)
- Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.
- Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment
- Weight > 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site
- Inability to hold breath for > 10 seconds
- Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., > 80 beats per minute at screening or prior to CCTA)
- Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA
- Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA
-
Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy < 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)
-
Unwilling or unable to receive specialty care per the trial protocol
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Ingen inngripen: Risk Factor-Based Care
The risk factor-based care group will be managed by their usual care providers, with an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. During the trial, the centralized cardiology team will monitor the provision of medications prescribed and lab values relative to guidelines, and provide feedback and education to site investigators to support optimization. CCTA results will be centrally archived and will remain blinded to the usual care provider until the end of the study. |
|
|
Eksperimentell: Cleerly Stage-Based Care
The Cleerly Stage-Based Care group will receive personalized care centrally managed by a remote cardiologist-led team. They will also receive an initial pre-randomization assessment of current treatment by a centralized cardiology team to optimize care relative to primary prevention guidelines. Cleerly CAD Staging System results will be discussed with participants and serve as the basis for standardized algorithm-supported pharmacotherapy & education, which will be intensified if plaque burden has progressed at 24 months. |
The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.
Tidsramme: Through study completion- an average of 3.5 years
|
The primary endpoint is total (first and subsequent) events for the composite endpoint of CV death, myocardial infarction (MI), ischemic stroke, acute limb ischemia, clinically driven arterial revascularization, and hospitalization or urgent visit for heart failure. |
Through study completion- an average of 3.5 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tidsramme: Through study completion- an average of 3.5 years
|
The secondary endpoints are time from randomization to first occurence of an event in the primary efficacy endpoint. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tidsramme: Through study completion- an average of 3.5 years
|
The secondary endpoints are total occurences after randomization of the primary efficacy endpoing, kidney failure, sustained estimated glomerular filtration rate (eGFR) decrease >40% from baseline, and death from renal causes. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tidsramme: Through study completion- an average of 3.5 years
|
The secondary endpoints are first and total occurrences after randomization of coronary death, MI, and urgent coronary revascularization. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tidsramme: Through study completion- an average of 3.5 years
|
The secondary endpoints are time from randomization to first occurrence of MI or ischemic stroke. |
Through study completion- an average of 3.5 years
|
|
The secondary objective is to compare Cleerly CAD stage-based care with risk factor-based care on other clinical events of CV and renal morbidity and mortality.
Tidsramme: Through study completion- an average of 3.5 years
|
The secondary endpoints are time from randomization to all-cause death. |
Through study completion- an average of 3.5 years
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
The safety objective is to assess harm with the 2 prevention strategies
Tidsramme: Through study completion- an average of 3.5 years
|
The safety endpoints are Adverse events (AE) leading to discontinuation of study-recommended medication (DAE), serious AE (SAE), adverse device effect (ADE). |
Through study completion- an average of 3.5 years
|
|
The safety objective is to assess harm with the 2 prevention strategies
Tidsramme: Through study completion- an average of 3.5 years
|
The safety endpoints are 20-item Short Form survey (SF-20). |
Through study completion- an average of 3.5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Samarbeidspartnere
Samarbeidspartnere
Etterforskere
Etterforskere
- Studiestol: Deepak Bhatt, MD, MPH, Mt. Sinai Heart
- Studiestol: David J. Maron, MD, FASPC, Stanford University
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Clerc OF, Fuchs TA, Stehli J, Benz DC, Grani C, Messerli M, Giannopoulos AA, Buechel RR, Luscher TF, Pazhenkottil AP, Kaufmann PA, Gaemperli O. Non-invasive screening for coronary artery disease in asymptomatic diabetic patients: a systematic review and meta-analysis of randomised controlled trials. Eur Heart J Cardiovasc Imaging. 2018 Aug 1;19(8):838-846. doi: 10.1093/ehjci/jey014.
- Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, Boehme AK, Buxton AE, Carson AP, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Ferguson JF, Generoso G, Ho JE, Kalani R, Khan SS, Kissela BM, Knutson KL, Levine DA, Lewis TT, Liu J, Loop MS, Ma J, Mussolino ME, Navaneethan SD, Perak AM, Poudel R, Rezk-Hanna M, Roth GA, Schroeder EB, Shah SH, Thacker EL, VanWagner LB, Virani SS, Voecks JH, Wang NY, Yaffe K, Martin SS. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. Circulation. 2022 Feb 22;145(8):e153-e639. doi: 10.1161/CIR.0000000000001052. Epub 2022 Jan 26.
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
Andre studie-ID-numre
- 202302CPC
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .